Curia finalizes LakePharma acquisition

By The Science Advisory Board staff writers

September 3, 2021 -- Curia has finalized its acquisition of LakePharma, a privately held biologics drug discovery, clinical research, and manufacturing organization.

With the acquisition, Curia, formerly known as Albany Molecular Research, said it can offer its expertise in both large and small molecules throughout each stage of the drug discovery and manufacturing process, including sterile injectable formulation and fill-finish production.

LakePharma will operate as part of Curia's R&D division. LakePharma and its "the biologics company" brand will migrate to Curia.

Curia to expand manufacturing capacity
Curia plans to expand its commercial manufacturing capacity at its facility in Rensselaer, NY, and is investing more than $35 million in the expanded...
Curia to acquire LakePharma
Curia, formerly known as Albany Molecular Research, has inked a deal to acquire private biologics firm LakePharma.
Curia to acquire Integrity Bio
Curia, formerly known as Albany Molecular Research, has inked a definitive agreement to acquire drug formulation and fill-finish provider Integrity Bio.
AMRI rebrands as Curia
Albany Molecular Research (AMRI) has changed its name to Curia, effective July 12.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter